- Home
- IAUX vs ADCT Comparison
IAUX vs ADCT Comparison
Compare IAUX & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IAUX
- ADCT
- Stock Information
- Founded
- IAUX 2020
- ADCT 2011
- Country
- IAUX United States
- ADCT Switzerland
- Employees
- IAUX N/A
- ADCT N/A
- Industry
- IAUX
- ADCT Biotechnology: Pharmaceutical Preparations
- Sector
- IAUX
- ADCT Health Care
- Exchange
- IAUX Nasdaq
- ADCT Nasdaq
- Market Cap
- IAUX 196.3M
- ADCT 224.3M
- IPO Year
- IAUX N/A
- ADCT 2020
- Fundamental
- Price
- IAUX $0.57
- ADCT $1.76
- Analyst Decision
- IAUX
- ADCT Strong Buy
- Analyst Count
- IAUX 0
- ADCT 5
- Target Price
- IAUX N/A
- ADCT $8.00
- AVG Volume (30 Days)
- IAUX 5.5M
- ADCT 709.5K
- Earning Date
- IAUX 03-12-2025
- ADCT 03-12-2025
- Dividend Yield
- IAUX N/A
- ADCT N/A
- EPS Growth
- IAUX N/A
- ADCT N/A
- EPS
- IAUX N/A
- ADCT N/A
- Revenue
- IAUX $52,944,000.00
- ADCT $70,717,000.00
- Revenue This Year
- IAUX N/A
- ADCT $6.81
- Revenue Next Year
- IAUX $127.90
- ADCT $11.23
- P/E Ratio
- IAUX N/A
- ADCT N/A
- Revenue Growth
- IAUX 30.02
- ADCT N/A
- 52 Week Low
- IAUX $0.34
- ADCT $1.68
- 52 Week High
- IAUX $1.78
- ADCT $6.04
- Technical
- Relative Strength Index (RSI)
- IAUX 47.73
- ADCT 41.61
- Support Level
- IAUX $0.53
- ADCT $1.68
- Resistance Level
- IAUX $0.64
- ADCT $2.14
- Average True Range (ATR)
- IAUX 0.04
- ADCT 0.14
- MACD
- IAUX 0.01
- ADCT 0.00
- Stochastic Oscillator
- IAUX 55.38
- ADCT 16.35
About IAUX i-80 Gold Corp.
i-80 Gold Corp is a well-financed gold and silver producer engaged in the exploration, development, and production of gold, silver, and poly-metallic deposits. The Company's principal assets include the Ruby Hill Mine, Lone Tree Mine, Granite Creek Mine, and McCoy-Cove Project.
About ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.